Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00519025 · ClinicalTrials.gov registry record
Risk Factors for Linezolid Resistance in Staphylococcus Aureus
A clinical trial of Staphylococcus Aureus and Linezolid Resistance, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 360
- Enrollment target
- 1
- Study location
NCT00519025 is a study of Staphylococcus Aureus and Linezolid Resistance that has completed, run by University of Pittsburgh. The registered enrollment target is 360 participants, below the 3,859-participant average among 8 other Staphylococcus Aureus trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00519025, a study of Staphylococcus Aureus and Linezolid Resistance, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 360 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a retrospective chart review study. The proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.
Conditions Studied
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2007-08 |
| Est. Completion | 2017-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00519025
The ClinicalTrials.gov registry entry for NCT00519025 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,859-participant average among 8 other Staphylococcus Aureus trials with a reported enrollment target (91% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Staphylococcus Aureus appearing as the primary indexed condition, and to 0 interventions.
NCT00519025 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00519025 about?
NCT00519025 is a clinical study titled "Risk Factors for Linezolid Resistance in Staphylococcus Aureus". This is a retrospective chart review study. The proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.
What is the current status of trial NCT00519025?
This trial is currently completed. The enrollment target is 360 participants. The study started on 2007-08. Estimated completion is 2017-06.
What conditions does trial NCT00519025 study?
This clinical trial studies the following conditions: Staphylococcus Aureus, Linezolid Resistance.
Who is sponsoring clinical trial NCT00519025?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00519025 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Staphylococcus Aureus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome
RECRUITING · Phase 1
-
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
RECRUITING · Phase 1
-
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
RECRUITING · Phase 4
-
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant
ACTIVE NOT RECRUITING · Phase 1
-
A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA
COMPLETED · NA
-
Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.